Buy Rimadyl Online, rx medicine for dogs

Rimadyl (Rx)

SKU: N/A Category:

Product Description

Rimadyl (Carprofen) 100 mg, 180 Caplets is a non-steroidal anti-inflammatory drug (NSAID) prescribed to treat pain and inflammation in dogs. In fact, Rimadyl fro dog is the number one brand of NSAID for dogs. It can be used to relieve arthritis pain, pain caused by hip or elbow dysplasia, or to control pain after some surgical procedures.

Rimadyl 100 mg Caplets work by inhibiting COX-2, an enzyme that triggers inflammation in the joints. Just give your pet the prescribed dose, and Rimadyl works for 24 hours to help keep your dog pain free. Unlike ibuprofen, which can be dangerous for dogs, Rimadyl is FDA-approved for canine pain relief. Help your arthritic dog stay mobile, active, and healthy with Rimadyl 100 mg, 180 Caplets.

However, if your dog does not readily accept the caplets, liver-flavored chewable tablets of Rimadyl are also available.

Rimadyl (carprofen) by Pfizer Animal Health is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class that includes ibuprofen, naproxen, and ketoprofen.

You can order the Rimadyl anti-inflammatory drug and other veterinary medicines for dogs at our online pet meds shop. At our Texas based veterinary drugs online shop, we offer discount veterinary medications.


For oral use in dogs only


Federal law restricts this pet med to use by or on the order of a licensed veterinarian.


  • Non-steroidal anti-inflammatory drug (NSAID) for dogs
  • Contains carprofen to reduce inflammation and joint pain in dogs
  • Effective treatment for symptoms of osteoarthritis in dogs
  • Powerful canine pain relief medication
  • Also comes in liver-flavored chewable tablets


Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models.

The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity.


Pfizer Animal Health’s Rimadyl is indicated for the relief of pain and inflammation in dogs associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.


Rimadyl pet med should not be used in dogs exhibiting previous hypersensitivity to carprofen.


Keep this canine pain relief medicine out of reach of children. Not for human use.

Consult a physician in cases of accidental ingestion by humans.

For use in dogs only.

Do not use this pet med in cats.

All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy.

Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered.

Owners should be advised to observe for signs of potential drug toxicity.


As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid.

When NSAIDs inhibit prostaglandins that cause inflammation in dogs they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients.

NSAID therapy could unmask occult disease which has previously been undiagnosed due to the absence of apparent clinical signs. Patients with underlying renal disease for example, may experience exacerbation or decompensation of their renal disease while on NSAID therapy.

The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAIDs perioperatively. Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiously, with appropriate monitoring. Concomitant use of Rimadyl dog medicine with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions, including gastrointestinal ulcerations and/or perforations. Sensitivity to drug-associated adverse reactions varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Rimadyl veterinary medications treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in healthy dogs.

Rimadyl pet med is not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand’s disease), as safety has not been established in dogs with these disorders. The safe use of Rimadyl dog medicines in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes or in lactating bitches has not been established.

Studies to determine the activity of Rimadyl dog medication for pain when administered concomitantly with other protein-bound or similarly metabolized drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy. Such dog medicines commonly used include cardiac, anticonvulsant and behavioral medications. It has been suggested that treatment with carprofen may reduce the level of inhalant anesthetics needed.

If additional dog medication for pain is warranted after administration of the total daily dose of Rimadyl, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.


Rimadyl for pain, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes.

Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death. Owners should be advised to discontinue Rimadyl for pain therapy and contact their veterinarian immediately if signs of intolerance are observed.

The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.


During investigational studies of osteoarthritis in dogs with twice daily administration of 1 mg/lb, no clinically significant adverse reactions were reported. Some clinical signs in arthritic dog were observed during field studies (n=297) which were similar for carprofen- and placebo-treated dogs. Incidences of the following were observed in both groups: vomiting (4%), diarrhea (4%), changes in appetite (3%), lethargy (1.4%), behavioral changes (1%), and constipation (0.3%). The product vehicle served as control.

There were no serious adverse events reported during clinical field studies of osteoarthritis in dogs with once daily administration of 2 mg/lb. The following categories of abnormal health observations were reported. The product vehicle served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Osteoarthritis Field Study (2 mg/lb once daily)

ObservationRimadyl (n=129)Placebo (n=132)
Diarrhea/Soft stool3.14.5
Behavior change0.80.8
SAP increase7.88.3
ALT increase5.44.5
AST increase2.30.8
BUN increase3.11.5

Clinical pathology parameters listed represent reports of increases from pre-treatment values; medical judgment is necessary to determine clinical relevance.

During investigational studies of surgical pain for the caplet formulation, no clinically significant adverse reactions were reported. The product vehicle served as control

Percentage of Dogs with Abnormal Health Observations Reported in Surgical Pain Field Studies with Caplets (2 mg/lb once daily)

Observation*Rimadyl (n=148)Placebo (n=149)
Diarrhea/Soft stool6.16.0
Ocular disease2.70
Dermatitis/skin lesion2.01.3
Oral/periodontal disease1.40
Urinary tract disease1.41.3
Wound drainage1.40

A single dog may have experienced more than one occurrence of an event.

Post-Approval Experience:

Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system.

Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.

Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function test(s), hyperbilirubinemia, bilirubinuria, hypoalbuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers.

Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation.

Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria.

Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.

Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis.

Dermatologic: Pruritus, increased shedding, alopecia, pyotraumatic moist dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventral ecchymosis.

Immunologic or hypersensitivity: Facial swelling, hives, erythema.

In rare situations, death has been associated with some of the adverse reactions listed above.

To report a suspected adverse reaction call 1-800-366-5288.


Always provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of Rimadyl and other treatment options before deciding to use Rimadyl for pain relief.

Use the lowest effective dose for the shortest duration consistent with individual response.

For oral administration, the manufacturer’s recommended dose is 2 mg of Rimadyl per 1 lb of bodyweight (4.4 mg/kg) given every 24 hours. However, the dose of this pet med can be divided and given every 12 hours as 1 mg per 1 lb of bodyweight (2.2 mg/kg). However, always follow your veterinarian’s specific instructions for administering Rimadyl to your pet.

For the control of postoperative pain, administer approximately 2 hours before the procedure. Caplets are scored and dosage should be calculated in half-caplet increments.


Confirmation of the effectiveness of Rimadyl for pain and inflammation relief in arthritic dogs, and for the control of postoperative pain associated with soft tissue and orthopedic surgeries was demonstrated in 5 placebo-controlled, masked studies examining the anti-inflammatory and analgesic effectiveness of Rimadyl caplets in various breeds of dogs.

Separate placebo-controlled, masked, multicenter field studies confirmed the anti-inflammatory and analgesic effectiveness of Rimadyl dog medication for pain when dosed at 2 mg/lb once daily or when divided and administered at 1 mg/lb twice daily. In these two field studies, dogs diagnosed with osteoarthritis showed statistically significant overall improvement based on lameness evaluations by the veterinarian and owner observations when administered Rimadyl at labeled doses.

Separate placebo-controlled, masked, multicenter field studies confirmed the effectiveness of Rimadyl for dogs for the control of postoperative pain when dosed at 2 mg/lb once daily in various breeds of dogs. In these studies, dogs presented for ovariohysterectomy, cruciate repair and aural surgeries were administered Rimadyl preoperatively and for a maximum of 3 days (soft tissue) or 4 days (orthopedic) postoperatively. In general, dogs administered Rimadyl dog medicines showed statistically significant improvement in joint pain in dogs scores compared to controls.


Store this dog medication for pain at controlled room temperature 15°-30°C (59°-86°F).


Rimadyl for pain are scored, and contain 25 mg, 75 mg, or 100 mg of carprofen per caplet.

Each caplet size is packaged in bottles containing 30, 60, or 180 caplets, or blister packs containing 4 cap.

Distributed by: Pfizer Animal Health, Div. of Pfizer Inc, NY, NY 10017

Additional Information

Bottle Size

100mg,180 Caplets, 100mg,180 Chewables, 100mg,30 Chewables, 100mg,60 Chewables, 25mg,180 Caplets, 25mg,180 Chewables, 25mg,30 Chewables, 25mg,60 Chewables, 75mg,180 Caplets, 75mg,180 Chewables, 75mg,30 Chewables, 75mg,60 Chewables

Product Type

Nutrition Medicine, OTC Medicine, Rx Medicine


There are no reviews yet.

Be the first to review “Rimadyl”

Your email address will not be published. Required fields are marked *